New pill takes on deadly brain cancer in early trial
NCT ID NCT07464925
First seen Mar 16, 2026 · Last updated May 02, 2026 · Updated 8 times
Summary
This early-phase study tests an experimental oral drug called GLIX1 in 30 adults whose aggressive brain tumor (high-grade glioma) has come back or worsened after standard treatments. The main goals are to find a safe dose and check for any signs that the drug can control the disease. Participants take GLIX1 capsules daily until the tumor progresses or side effects become unacceptable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
NOT_YET_RECRUITINGTampa, Florida, 33612, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern Medicine
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.